| __timestamp | Geron Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20707000 | 47795223 |
| Thursday, January 1, 2015 | 17831000 | 50426000 |
| Friday, January 1, 2016 | 18047000 | 70853000 |
| Sunday, January 1, 2017 | 11033000 | 78168000 |
| Monday, January 1, 2018 | 13432000 | 123757000 |
| Tuesday, January 1, 2019 | 52072000 | 140963000 |
| Wednesday, January 1, 2020 | 51488000 | 131773000 |
| Friday, January 1, 2021 | 85727000 | 210328000 |
| Saturday, January 1, 2022 | 95518000 | 235780000 |
| Sunday, January 1, 2023 | 125046000 | 244990000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Geron Corporation and Travere Therapeutics, Inc. have demonstrated distinct strategies in their R&D allocations. From 2014 to 2023, Travere Therapeutics consistently outpaced Geron, with R&D expenses peaking at approximately $245 million in 2023, a 413% increase from 2014. In contrast, Geron Corporation's R&D spending grew by 504% over the same period, reaching around $125 million in 2023. This divergence highlights Travere's aggressive investment in research, while Geron shows a more measured, yet significant, increase. These trends underscore the dynamic nature of biotech innovation, where strategic R&D investments can shape the future of medical breakthroughs.
R&D Insights: How Sanofi and Geron Corporation Allocate Funds
R&D Spending Showdown: Genmab A/S vs Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Verona Pharma plc vs Travere Therapeutics, Inc.
Research and Development Investment: Viking Therapeutics, Inc. vs Travere Therapeutics, Inc.
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Travere Therapeutics, Inc. vs Xencor, Inc.